BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

Summary

To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.

Timeline

Start

2022-02-01

Primary completion

2023-12

Completion

2025-01

Outcome

Outcome not reported

Stopped: “Drug unavailable”

Drugs

Indications